Dennis Ongarora

Dr. Dennis Ongarora

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2014 in Chemical Reviews
Verified
Journal Article
Closed access
MNMathew Njoroge
Mathew Njoroge
NNNicholas M. Njuguna
Nicholas M. Njuguna
PMPeggoty Mutai
Peggoty Mutai
DODennis Ongarora
Dennis Ongarora
PSPaul W. Smith
Paul W. Smith
KCKelly Chibale
Kelly Chibale

1 August 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DODennis Ongarora
Dennis Ongarora
JGJiri Gut
Jiri Gut
PRPhilip J. Rosenthal
Philip J. Rosenthal
CMCollen Masimirembwa
Collen Masimirembwa
KCKelly Chibale
Kelly Chibale

24 April 2019 in Pharmacy
Verified
Journal Article
Open access
PDF file
DODennis Ongarora
Dennis Ongarora
JKJamlick Karumbi
Jamlick Karumbi
WMWarnyta Minnaard
Warnyta Minnaard
KAKennedy Abuga
Kennedy Abuga
VOVincent Okungu
Vincent Okungu
IKIsaac Kibwage
Isaac Kibwage
Medicine prices are a major determinant of access to healthcare. Owing to low availability of medicines in the public health facilities and poor accessibility to these facilities, most low-income residents pay out-of-pocket for health services and transport to the private health facilities. In low-income settlements, high retail prices are likely to push the population further into poverty and ill health. This study assessed the retail pricing, availability, and affordability of medicines in private health facilities in low-income settlements within Nairobi County. Medicine prices and availability data were collected between September and December 2016 at 45 private healthcare facilities in 14 of Nairobi’s low-income settlements using electronic questionnaires. The International Medical Products Price Guide provided international medicine reference prices for comparison. Affordability and availability proxies were calculated according to existing methods. Innovator brands were 13.8 times more expensive than generic brands. The lowest priced generics and innovator brands were, on average, sold at 2.9 and 32.6 times the median international reference prices of corresponding medicines. Assuming a 100% disposable income, it would take 0.03 to 1.33 days’ wages for the lowest paid government employee to pay for treatment courses of selected single generic medicines. Medicine availability in the facilities ranged between 2% and 76% (mean 43%) for indicator medicines. Prices of selected medicines varied within the 14 study regions. Retail medicine prices in the low-income settlements studied were generally higher than corresponding international reference prices. Price variations were observed across different regions although the regions comprise similar socioeconomic populations. These factors are likely to impact negatively on healthcare access.

13 September 2012 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
NNNicholas M Njuguna
Nicholas M Njuguna
DODennis Ongarora
Dennis Ongarora
KCKelly Chibale
Kelly Chibale
Introduction: The isolation of artemisinin from an ancient Chinese remedy in the early 1970s heralded the beginning of a new era in antimalarial drug therapy culminating in artemisinin-based combination therapies currently being the mainstay of malaria treatment worldwide. Ongoing research on this compound and its derivatives has revealed its potential use in treating other infectious and noninfectious diseases. Areas covered: This review provides a summary of patents published globally from January 2006 to June 2012 covering promising artemisinin derivatives and artemisinin-based drug combinations developed for use in various therapeutic areas. Expert opinion: The diversity of semi-synthetic artemisinin derivatives has been limited to the same design strategy of modifying the artemisinin molecule at the same positions due to inherent synthetic challenges. To address this, future endeavors should include: the use of biotransformation strategies to modify other positions in the sesquiterpene ring while retaining the endoperoxide bridge; the design and synthesis of synthetic ozonides based on the pharmacophoric endoperoxide motif and drug repositioning approaches to artemisinin-based combination therapy. A better understanding of the mechanism of action of artemisinin derivatives and their biomolecular targets may provide an invaluable tool for the development of derivatives with a wider array of activity and greater clinical utility than currently appreciated.

1 September 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
DODennis Ongarora
Dennis Ongarora
NSNatasha Strydom
Natasha Strydom
KWKathryn Wicht
Kathryn Wicht
MNMathew Njoroge
Mathew Njoroge
LWLubbe Wiesner
Lubbe Wiesner
KCKelly Chibale
Kelly Chibale

25 December 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Smith BabiakaSmith Babiaka
Smith Babiaka
Conrad Simoben VeransoConrad Simoben Veranso
Conrad Simoben Veranso
KAKennedy Abuga
Kennedy Abuga
JMJames A. Mbah
James A. Mbah
RKRajshekhar Karpoormath
Rajshekhar Karpoormath
Fidele Ntie-KangFidele Ntie-Kang
Fidele Ntie-Kang
A new iboga-vobasine-type isomeric bisindole alkaloid named voacamine A (1), along with eight known compounds—voacangine (2), voacristine (3), coronaridine (4), tabernanthine (5), iboxygaine (6), voacamine (7), voacorine (8) and conoduramine (9)—were isolated from the stem bark of Voacangaafricana. The structures of the compounds were determined by comprehensive spectroscopic analyses. Compounds 1, 2, 3, 4, 6, 7 and 8 were found to inhibit the motility of both the microfilariae (Mf) and adult male worms of Onchocerca ochengi, in a dose-dependent manner, but were only moderately active on the adult female worms upon biochemical assessment at 30 μM drug concentrations. The IC50 values of the isolates are 2.49–5.49 µM for microfilariae and 3.45–17.87 µM for adult males. Homology modeling was used to generate a 3D model of the O. ochengi thioredoxin reductase target and docking simulation, followed by molecular dynamics and binding free energy calculations attempted to offer an explanation of the anti-onchocercal structure–activity relationship (SAR) of the isolated compounds. These alkaloids are new potential leads for the development of antifilarial drugs. The results of this study validate the traditional use of V. africana in the treatment of human onchocerciasis.